期刊文献+

比阿培南对501株临床分离致病菌的体外抗菌活性研究 被引量:19

Studies on Anti-microbe Actitivy in vitro of Biapenem Against 501 Strains of Bacteria Isolated
下载PDF
导出
摘要 目的:评价比阿培南对501株临床分离致病菌的体外抗菌活性。方法:采用刃天青微孔板稀释法测定比阿培南和对照品(美罗培南、亚胺培南、头孢吡肟、头孢他啶、头孢哌酮/舒巴坦、环丙沙星、苯唑西林、万古霉素)对501株临床分离致病菌的体外抗菌活性。结果:比阿培南对大肠埃希菌、克雷伯菌属、产气肠杆菌、阴沟肠杆菌、志贺菌属、沙门菌属、变形杆菌属、沙雷菌属、柠檬酸菌属、不动杆菌属和铜绿假单胞菌的MIC50分别为0.06,0.13,0.25,0.13,0.03,0.03,1.00,0.50,0.13,0.13,0.50μg/mL;MIC90分别为0.13,0.13,0.50,0.50,0.03,0.06,1.00,0.50,0.25,0.25,4.00μg/mL。结论:比阿培南对临床分离致病菌的最低抑菌浓度MIC50、MIC90低于对照品。 Objective: To evaluate antimierobe activity in vitro of biapcnem against 501 strains of bacteria isolated. Methods: Susceptibility of 501 swains of bacteria isolated to biapencm, meropcnem, imipcnem, cefepime, ciprofloxacin, cefopcrazone/sulbactam, ceflazidime, oxacillin and vancomycin were detected by microtitre plate-based antibacterial resazurin assay. Results: MICro of biapcnem against Escherickia, Klebsiella, Enterobacter, Shigella, Salmonella, Proteus, Serratia, Citrobacter and Pseudomonas aerugnosa are 0.125, 0.125, 0.50, 0.50, 0.03, 0.06, 0.25, 1.00, 0.50, 0.25 and 4.00 μg/mL, respectively; better than meropenem and imipenem. Conclusions: Minimum inhibitory concentrafion(MIC50, MIC90)of biapenem against 501 strains of bacteria isolated was lower than that of control antibiotics.
出处 《抗感染药学》 2009年第3期191-193,共3页 Anti-infection Pharmacy
关键词 比阿培南 致病菌 抗菌活性 biapenem pathogenic bacteria antibiotic actitivy
  • 相关文献

参考文献4

  • 1Perry CM,Ibbotson T.Biapenem[J].Drugs,2002,62(15):2 221-2234.
  • 2Sarker SD,Nahar L,Kumarasamy Y.Microtitre plate-based antibacterial assay incorporating resazlnin as an indicator of cell growth,and its application in the in vitro antibacterial screening of phytochcmicals[J].Methods,2007,42:321-324.
  • 3Malanosld GJ,Collins L,Wennersten C,et al.In vitro actitivy of biapenem against clinical isolates of gram-positive and gramnegitive bacteria[J].Antimicrob Agents Chemother,1993,37(9):2 009-2 016.
  • 4杨帆,赵旭,吴菊芳,周新,修清玉,施毅,沈策,刘荣玉,张伯科,钟玲,陈楠,倪兆慧,苏炳华,吴湜,张婴元.比阿培南治疗细菌性肺炎和尿路感染的多中心随机对照临床试验[J].中国感染与化疗杂志,2007,7(2):73-78. 被引量:28

二级参考文献6

  • 1Hara K,Baba S,Matsumoto F,et al.Clinical evaluation of biapenem in various infectious diseases[J].Jpn J Antibiot,1999,52(11):629-660.
  • 2Toynaga Y,Ishihara T,Tezuka T,et al.Pharmacokinetic and clinical studies on biapenem(L-627) in the pediatric field[J].Jpn J Antibiot,1994,47(12):1691-1705.
  • 3Matsuda S,Oh K,Ando S,et al.Basic and clinical studies on biapenem (L-627) in obstetrics and gynecology[J].Jpn J Antibiot.1994,47(12):1637-1667.
  • 4Perry CM,IbbotsonT.Biapenem[J].Drugs,2002,62(15):2221-2234.
  • 5Kohno S,Tomono K,Maesaki S,et al.Comparison of four carbapenems; imipenem-cilastatin,panipenem-betamipron,meropenem,and biapenem with review of cliniacal trails in Japan[J].Acta Med Nagasaki,1998,43(1):12-18.
  • 6Brismar B,Akerlund JE,Sjostedt S,et al.Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominalinfections:report from a Swedish study group[J].Scand J Infect Dis,1996,28(5):507-512.

共引文献27

同被引文献130

引证文献19

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部